PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The objective of this study was to investigate the feasibility of a PD-1 inhibitor in combination with progesterone as a means of preserving fertility in patients with early-stage mismatch repair-deficient (MMRd) endometrial cancer who wish to preserve fertility.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: f
View:
• Be between the ages of 18-45 years old;
• Stage IA (FIGO 2009) ;
• Confirmed diagnosis of endometrial adenocarcinoma G1-G2 based upon D\&C or hysteroscopy;
• Molecular classification of MMRd, determined by immunohistochemical (IHC) for MMR proteins and by the second generation sequencing (NGS) or microsatellite polymerase chain reaction (PCR);
• With a strong desire for fertility preservation;
• Sign the informed consent.
Locations
Other Locations
China
Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Jianliu Wang, Professor
wangjianliu1203@163.com
0086-010-88324381
Backup
Yiqin Wang
emily_wang92@163.com
Time Frame
Start Date: 2024-09-02
Estimated Completion Date: 2029-10
Participants
Target number of participants: 10
Treatments
Experimental: PD-1 Inhibitor Combined With Progesterone Treatment
All participants
Related Therapeutic Areas
Sponsors
Collaborators: Tianjin Medical University, Peking Union Medical College Hospital, Shandong University, Peking University Third Hospital, Beijing Chao Yang Hospital, Huazhong University of Science and Technology, Shengjing Hospital
Leads: Peking University People's Hospital